carbamates has been researched along with Alveolitis, Fibrosing in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "These findings demonstrate that AM966 is a potent, selective, orally bioavailable LPA(1) receptor antagonist that may be beneficial in treating lung injury and fibrosis, as well as other diseases that are characterized by pathological inflammation, oedema and fibrosis." | 1.36 | A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. ( Baccei, CS; Bundey, RA; Chapman, C; Correa, LD; Evans, JF; Fagan, P; Hutchinson, JH; Lorrain, DS; Parr, TA; Prasit, P; Prodanovich, PC; Santini, AM; Seiders, TJ; Stebbins, KJ; Swaney, JS, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Swaney, JS | 1 |
| Chapman, C | 1 |
| Correa, LD | 1 |
| Stebbins, KJ | 1 |
| Bundey, RA | 1 |
| Prodanovich, PC | 1 |
| Fagan, P | 1 |
| Baccei, CS | 1 |
| Santini, AM | 1 |
| Hutchinson, JH | 1 |
| Seiders, TJ | 1 |
| Parr, TA | 1 |
| Prasit, P | 1 |
| Evans, JF | 1 |
| Lorrain, DS | 1 |
1 other study available for carbamates and Alveolitis, Fibrosing
| Article | Year |
|---|---|
A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.
Topics: Administration, Oral; Animals; Bleomycin; Bronchoalveolar Lavage Fluid; Calcium; Carbamates; Cell Li | 2010 |